0000899243-17-023131.txt : 20171002
0000899243-17-023131.hdr.sgml : 20171002
20171002163619
ACCESSION NUMBER: 0000899243-17-023131
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20171002
FILED AS OF DATE: 20171002
DATE AS OF CHANGE: 20171002
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Benz Edward J. JR
CENTRAL INDEX KEY: 0001691160
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38219
FILM NUMBER: 171114907
MAIL ADDRESS:
STREET 1: C/O DECIPHERA PHARMACEUTICALS, LLC
STREET 2: 500 TOTTEN POND ROAD
CITY: WALTHAM
STATE: MA
ZIP: 02451
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Deciphera Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001654151
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 200299725
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 500 TOTTEN POND ROAD
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: 781-209-6400
MAIL ADDRESS:
STREET 1: 500 TOTTEN POND ROAD
CITY: WALTHAM
STATE: MA
ZIP: 02451
FORMER COMPANY:
FORMER CONFORMED NAME: Deciphera Pharmaceuticals, LLC
DATE OF NAME CHANGE: 20150928
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2017-10-02
0
0001654151
Deciphera Pharmaceuticals, Inc.
DCPH
0001691160
Benz Edward J. JR
C/O DECIPHERA PHARMACEUTICALS, INC.
500 TOTTEN POND ROAD
WALTHAM
MA
02451
1
0
0
0
Stock Option (Right to Buy)
3.95
2017-10-02
4
M
0
6236
D
2026-09-26
Common Stock
35233
0
D
Stock Option (Right to Buy)
3.95
2017-10-02
4
M
0
35233
A
2026-09-26
Common Stock
35233
35233
D
Stock Option (Right to Buy)
6.13
2017-10-02
4
M
0
1271
D
2027-06-03
Common Stock
7181
0
D
Stock Option (Right to Buy)
6.13
2017-10-02
4
M
0
7181
A
2027-06-03
Common Stock
7181
7181
D
Immediately prior to the closing of the Issuer's initial public offering, these options to purchase common stock of Deciphera Pharmaceuticals, LLC were exchanged for options to purchase common stock of the Issuer on a 1 for 5.65 basis pursuant to that certain Reorganization Agreement and Plan of Merger by and among the Issuer, Deciphera Pharmaceuticals, LLC and the other parties named therein, dated September 26, 2017 (the "Merger Agreement"). These transactions were exempt from Section 16(b) in reliance upon Rule 16b-3 and Rule 16b-6(b).
This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option vests in 48 equal monthly installments at the end of each month following the vesting commencement date of September 27, 2016, subject to continued service through such dates.
Represents the total number of options to purchase common stock of the Issuer received upon the exchange of options to purchase common stock of Deciphera Pharmaceuticals, Inc. for options to purchase common stock of the Issuer pursuant to the Merger Agreement.
This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option vests in 48 equal monthly installments at the end of each month following the vesting commencement date of May 26, 2017, subject to continued service through such dates.
/s/ Thomas P. Kelly, Attorney-in-Fact
2017-10-02